AHRQ study: Ortho patients, those admitted through ED most likely to be readmitted

Three-quarters of patients readmitted to a hospital after being discharged return to the same hospital, according to a study funded by the Agency for Healthcare Research and Quality (AHRQ).

Patients admitted for orthopedic conditions and patients who entered the hospital through the emergency department were the most likely to have a same-hospital readmission, according to findings.

The highest rates overall for readmission were found in patients aged 65 to 84, though patients aged 45 to 64 who underwent spinal fusion had similar readmission rates. The condition most commonly associated with readmission was heart failure, and the conditions for which a readmission was least likely were hip and knee arthroplasty. Women made up a larger portion of readmissions across all conditions, except for heart attack.

Investigators used the State Inpatient Databases, a component of AHRQ’s Healthcare Cost and Utilization Project (HCUP), to conduct the study. They analyzed data on adults discharged from hospitals in 16 states. HCUP is the nation’s most comprehensive source of hospital data, including information on inpatient care, ambulatory care and emergency department visits. The study, “Patient Factors Contributing to Variation in Same-Hospital Readmission Rate,” and abstract were published in Medical Care Research and Review.

Beth Walsh,

Editor

Editor Beth earned a bachelor’s degree in journalism and master’s in health communication. She has worked in hospital, academic and publishing settings over the past 20 years. Beth joined TriMed in 2005, as editor of CMIO and Clinical Innovation + Technology. When not covering all things related to health IT, she spends time with her husband and three children.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.